| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Alpha-2A adrenergic receptor |
|---|
| Ligand | BDBM85709 |
|---|
| Substrate/Competitor | n/a |
|---|
| Ki | 0.631±n/a nM |
|---|
| Comments | PDSP_3303 |
|---|
| Citation |  Millan, MJ; Dekeyne, A; Newman-Tancredi, A; Cussac, D; Audinot, V; Milligan, G; Duqueyroix, D; Girardon, S; Mullot, J; Boutin, JA; Nicolas, JP; Renouard-Try, A; Lacoste, JM; Cordi, A S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther295:1192-205 (2000) [PubMed] |
|---|
| More Info.: | Get all data from this article |
|---|
| |
| Alpha-2A adrenergic receptor |
|---|
| Name: | Alpha-2A adrenergic receptor |
|---|
| Synonyms: | ADA2A_HUMAN | ADRA2A | ADRA2R | ADRAR | Adrenergic alpha2A | Adrenergic receptor alpha | Alpha-2 adrenergic receptor subtype C10 | Alpha-2A adrenoceptor | Alpha-2A adrenoreceptor | Alpha-2AAR | alpha-2A adrenergic receptor [Homo sapiens] |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 48979.91 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P08913 |
|---|
| Residue: | 450 |
|---|
| Sequence: | MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFT
SRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSS
IVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGG
PQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVA
APPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSD
HAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKAS
RWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSS
LNPVIYTIFNHDFRRAFKKILCRGDRKRIV
|
|
|
|---|
| BDBM85709 |
|---|
| n/a |
|---|
| Name | BDBM85709 |
|---|
| Synonyms: | S18616 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C12H14N2O |
|---|
| Mol. Mass. | 202.2524 |
|---|
| SMILES | NC1=NC2(CO1)CCc1ccccc1C2 |t:1| |
|---|
| Structure | 
|
|---|
Search and Browse
